Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance

Joshua J. Souchek, Lindsey Muraskin, Lucas Houser, Quyen Vu, Aaron M Mohs

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Aberrant metabolism mechanisms are a well-established hallmark of cancer. Exploiting tumor metabolism as a therapeutic target is being actively pursued. De novo synthesis of fatty acids by fatty acid synthase (FASN) is a particularly attractive mechanism to target because increased lipid synthesis is associated with more aggressive tumor. In particular, our work focuses on the reformulation of orlistat, an FDA-approved lipase inhibitor that also inhibits the thioesterase domain of FASN. We report on the rationale, synthesis, efficacy, delivery, and limitations of a novel nanoparticle formulation of orlistat in the goal of targeting the FASN pathway.

Original languageEnglish (US)
Title of host publicationVisualizing and Quantifying Drug Distribution in Tissue III
EditorsKin Foong Chan, Conor L. Evans
PublisherSPIE
ISBN (Electronic)9781510623606
DOIs
StatePublished - Jan 1 2019
EventVisualizing and Quantifying Drug Distribution in Tissue III 2019 - San Francisco, United States
Duration: Feb 2 2019 → …

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume10859
ISSN (Print)1605-7422

Conference

ConferenceVisualizing and Quantifying Drug Distribution in Tissue III 2019
CountryUnited States
CitySan Francisco
Period2/2/19 → …

Fingerprint

Fatty Acid Synthases
fatty acids
Fatty acids
Tumors
tumors
Metabolism
metabolism
Growth
Neoplasms
synthesis
Lipase
Nanoparticles
Lipases
Fatty Acids
inhibitors
Lipids
lipids
delivery
cancer
formulations

Keywords

  • Chemoresistance
  • Drug delivery
  • Fatty acid synthase (FASN)
  • Hyaluronic acid
  • Lipogenesis
  • Nanoparticle
  • Synergy
  • Tumor metabolism

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Biomaterials
  • Radiology Nuclear Medicine and imaging

Cite this

Souchek, J. J., Muraskin, L., Houser, L., Vu, Q., & Mohs, A. M. (2019). Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance. In K. F. Chan, & C. L. Evans (Eds.), Visualizing and Quantifying Drug Distribution in Tissue III [1085909] (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 10859). SPIE. https://doi.org/10.1117/12.2512244

Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance. / Souchek, Joshua J.; Muraskin, Lindsey; Houser, Lucas; Vu, Quyen; Mohs, Aaron M.

Visualizing and Quantifying Drug Distribution in Tissue III. ed. / Kin Foong Chan; Conor L. Evans. SPIE, 2019. 1085909 (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 10859).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Souchek, JJ, Muraskin, L, Houser, L, Vu, Q & Mohs, AM 2019, Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance. in KF Chan & CL Evans (eds), Visualizing and Quantifying Drug Distribution in Tissue III., 1085909, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, vol. 10859, SPIE, Visualizing and Quantifying Drug Distribution in Tissue III 2019, San Francisco, United States, 2/2/19. https://doi.org/10.1117/12.2512244
Souchek JJ, Muraskin L, Houser L, Vu Q, Mohs AM. Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance. In Chan KF, Evans CL, editors, Visualizing and Quantifying Drug Distribution in Tissue III. SPIE. 2019. 1085909. (Progress in Biomedical Optics and Imaging - Proceedings of SPIE). https://doi.org/10.1117/12.2512244
Souchek, Joshua J. ; Muraskin, Lindsey ; Houser, Lucas ; Vu, Quyen ; Mohs, Aaron M. / Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance. Visualizing and Quantifying Drug Distribution in Tissue III. editor / Kin Foong Chan ; Conor L. Evans. SPIE, 2019. (Progress in Biomedical Optics and Imaging - Proceedings of SPIE).
@inproceedings{b9b149640cf94bc9945cbd1d859a637e,
title = "Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance",
abstract = "Aberrant metabolism mechanisms are a well-established hallmark of cancer. Exploiting tumor metabolism as a therapeutic target is being actively pursued. De novo synthesis of fatty acids by fatty acid synthase (FASN) is a particularly attractive mechanism to target because increased lipid synthesis is associated with more aggressive tumor. In particular, our work focuses on the reformulation of orlistat, an FDA-approved lipase inhibitor that also inhibits the thioesterase domain of FASN. We report on the rationale, synthesis, efficacy, delivery, and limitations of a novel nanoparticle formulation of orlistat in the goal of targeting the FASN pathway.",
keywords = "Chemoresistance, Drug delivery, Fatty acid synthase (FASN), Hyaluronic acid, Lipogenesis, Nanoparticle, Synergy, Tumor metabolism",
author = "Souchek, {Joshua J.} and Lindsey Muraskin and Lucas Houser and Quyen Vu and Mohs, {Aaron M}",
year = "2019",
month = "1",
day = "1",
doi = "10.1117/12.2512244",
language = "English (US)",
series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
publisher = "SPIE",
editor = "Chan, {Kin Foong} and Evans, {Conor L.}",
booktitle = "Visualizing and Quantifying Drug Distribution in Tissue III",

}

TY - GEN

T1 - Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance

AU - Souchek, Joshua J.

AU - Muraskin, Lindsey

AU - Houser, Lucas

AU - Vu, Quyen

AU - Mohs, Aaron M

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aberrant metabolism mechanisms are a well-established hallmark of cancer. Exploiting tumor metabolism as a therapeutic target is being actively pursued. De novo synthesis of fatty acids by fatty acid synthase (FASN) is a particularly attractive mechanism to target because increased lipid synthesis is associated with more aggressive tumor. In particular, our work focuses on the reformulation of orlistat, an FDA-approved lipase inhibitor that also inhibits the thioesterase domain of FASN. We report on the rationale, synthesis, efficacy, delivery, and limitations of a novel nanoparticle formulation of orlistat in the goal of targeting the FASN pathway.

AB - Aberrant metabolism mechanisms are a well-established hallmark of cancer. Exploiting tumor metabolism as a therapeutic target is being actively pursued. De novo synthesis of fatty acids by fatty acid synthase (FASN) is a particularly attractive mechanism to target because increased lipid synthesis is associated with more aggressive tumor. In particular, our work focuses on the reformulation of orlistat, an FDA-approved lipase inhibitor that also inhibits the thioesterase domain of FASN. We report on the rationale, synthesis, efficacy, delivery, and limitations of a novel nanoparticle formulation of orlistat in the goal of targeting the FASN pathway.

KW - Chemoresistance

KW - Drug delivery

KW - Fatty acid synthase (FASN)

KW - Hyaluronic acid

KW - Lipogenesis

KW - Nanoparticle

KW - Synergy

KW - Tumor metabolism

UR - http://www.scopus.com/inward/record.url?scp=85065763946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065763946&partnerID=8YFLogxK

U2 - 10.1117/12.2512244

DO - 10.1117/12.2512244

M3 - Conference contribution

T3 - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

BT - Visualizing and Quantifying Drug Distribution in Tissue III

A2 - Chan, Kin Foong

A2 - Evans, Conor L.

PB - SPIE

ER -